apalutamide

February 16, 2018February 16, 2018

First Therapy for Non-metastatic, Castration-resistant Prostate Cancer Patients Approved in US

News

The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s Erleada (apalutamide), a next-generation androgen receptor inhibitor, as therapy for patients with localized (non-metastatic) prostate cancer who failed to respond ... Read more

January 2, 2018January 2, 2018

FDA Grants Janssen Biotech’s Apalutamide Priority Review Designation to Treat Non-metastatic CRPC

News

The U.S. Food and Drug Administration (FDA) has granted priority review status to apalutamide — an investigational androgen receptor inhibitor — to treat men with non-metastatic castration-resistant prostate cancer (CRPC). This ... Read more

October 13, 2017

Janssen Seeks Approval of Apalutamide for Non-metastatic Castration-resistant Prostate Cancer

News

Janssen Biotech has submitted a new drug application to the U.S. Food and Drug Administration (FDA) for an investigational, next-generation therapy called apalutamide (ARN-509) to treat non-metastatic castration-resistant prostate cancer. ... Read more